BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 11777267)

  • 1. The promise of T-lymphocyte immunotherapy for the treatment of malignant disease.
    Thomas AK; June CH
    Cancer J; 2001; 7 Suppl 2():S67-75. PubMed ID: 11777267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell therapy after hematopoietic stem cell transplantation.
    Kennedy-Nasser AA; Brenner MK
    Curr Opin Hematol; 2007 Nov; 14(6):616-24. PubMed ID: 17898565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploiting beneficial alloreactive T cells.
    Barber LD; Madrigal JA
    Vox Sang; 2006 Jul; 91(1):20-7. PubMed ID: 16756597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse.
    Wysoczanska B; Bogunia-Kubik K; Dlubek D; Jaskula E; Sok A; Drabczak-Skrzypek D; Sedzimirska M; Lange A
    Transplant Proc; 2007 Nov; 39(9):2898-901. PubMed ID: 18022011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive T-cell therapy of cancer.
    Yee C
    Hematol Oncol Clin North Am; 2006 Jun; 20(3):711-33. PubMed ID: 16762731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance.
    Mapara MY; Sykes M
    J Clin Oncol; 2004 Mar; 22(6):1136-51. PubMed ID: 15020616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy in allogeneic hematopoietic stem cell transplantation--not just a case for effector cells.
    Troeger A; Meisel R; Moritz T; Dilloo D
    Bone Marrow Transplant; 2005 Mar; 35 Suppl 1():S59-64. PubMed ID: 15812533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy with alloreactive T-cells?
    Madrigal AJ; Rusakiewicz S; Dodi AI; Rees R
    Hematol J; 2004; 5 Suppl 3():S91-5. PubMed ID: 15190286
    [No Abstract]   [Full Text] [Related]  

  • 10. [Minor antigens - major impact. The role of minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation].
    Hudecek M; Bartsch K; Tschiedel S; Niederwieser D
    Dtsch Med Wochenschr; 2008 Jul; 133(28-29):1511-6. PubMed ID: 18597211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell reconstitution and expansion after hematopoietic stem cell transplantation: 'T' it up!
    Porter DL; June CH
    Bone Marrow Transplant; 2005 May; 35(10):935-42. PubMed ID: 15806121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular therapy to control tumor progression.
    Kapp M; Rasche L; Einsele H; Grigoleit GU
    Curr Opin Hematol; 2009 Nov; 16(6):437-43. PubMed ID: 19587587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Alloreactive donor lymphocytes (DLI) after allogeneic hematopoietic stem cell transplantation (HSCT): study of toxicity and efficacy].
    Michallet AS; Nicolini F; Michallet M
    Bull Cancer; 2003; 90(8-9):758-62. PubMed ID: 14609766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donor lymphocyte infusion. An adaptive cellular immunotherapy for treatment of hematological malignancies.
    Owaidah TM
    Saudi Med J; 2003 Feb; 24(2):138-41. PubMed ID: 12682675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minor histocompatibility antigens as targets of cellular immunotherapy in leukaemia.
    Falkenburg JH; Willemze R
    Best Pract Res Clin Haematol; 2004 Sep; 17(3):415-25. PubMed ID: 15498713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of the allogeneic TCR repertoire to enhance anti-tumor immunity.
    Xue S; Gillmore R; Gao L; Bendle G; Holler A; Downs AM; Tsallios A; Ramirez F; Ghani Y; Hart D; Alcock S; Tranter A; Morris E; Stauss HJ
    J Biol Regul Homeost Agents; 2004; 18(2):131-3. PubMed ID: 15471216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Considerations on clinical use of T cell immunotherapy for cancer.
    Plautz GE; Cohen PA; Shu S
    Arch Immunol Ther Exp (Warsz); 2003; 51(4):245-57. PubMed ID: 12956434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination for leukemia.
    Molldrem JJ
    Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 1):13-8. PubMed ID: 16399579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic redirection of T cells for cancer therapy.
    Westwood JA; Kershaw MH
    J Leukoc Biol; 2010 May; 87(5):791-803. PubMed ID: 20179152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Possibility of selective induction of a GVL effect without increasing GVHD].
    Akatsuka Y
    Rinsho Ketsueki; 2008 Aug; 49(8):607-15. PubMed ID: 18800609
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.